Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.14
INCY's Cash to Debt is ranked lower than
79% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. INCY: 1.14 )
Ranked among companies with meaningful Cash to Debt only.
INCY' s Cash to Debt Range Over the Past 10 Years
Min: 0.5  Med: 1.19 Max: No Debt
Current: 1.14
Equity to Asset 0.17
INCY's Equity to Asset is ranked lower than
91% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. INCY: 0.17 )
Ranked among companies with meaningful Equity to Asset only.
INCY' s Equity to Asset Range Over the Past 10 Years
Min: -0.95  Med: 0.05 Max: 0.78
Current: 0.17
-0.95
0.78
Interest Coverage 1.11
INCY's Interest Coverage is ranked lower than
95% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INCY: 1.11 )
Ranked among companies with meaningful Interest Coverage only.
INCY' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 0.32 Max: 1.11
Current: 1.11
0.02
1.11
F-Score: 7
Z-Score: 8.96
M-Score: -1.66
WACC vs ROIC
6.85%
80.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 6.72
INCY's Operating margin (%) is ranked higher than
75% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. INCY: 6.72 )
Ranked among companies with meaningful Operating margin (%) only.
INCY' s Operating margin (%) Range Over the Past 10 Years
Min: -4064.53  Med: -78.07 Max: 8.27
Current: 6.72
-4064.53
8.27
Net-margin (%) 0.87
INCY's Net-margin (%) is ranked higher than
69% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. INCY: 0.87 )
Ranked among companies with meaningful Net-margin (%) only.
INCY' s Net-margin (%) Range Over the Past 10 Years
Min: -4565.45  Med: -110.46 Max: 0.87
Current: 0.87
-4565.45
0.87
ROE (%) 17.00
INCY's ROE (%) is ranked higher than
90% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. INCY: 17.00 )
Ranked among companies with meaningful ROE (%) only.
INCY' s ROE (%) Range Over the Past 10 Years
Min: 14.59  Med: 14.59 Max: 14.59
Current: 17
ROA (%) 0.72
INCY's ROA (%) is ranked higher than
77% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. INCY: 0.72 )
Ranked among companies with meaningful ROA (%) only.
INCY' s ROA (%) Range Over the Past 10 Years
Min: -70.43  Med: -18.85 Max: 0.72
Current: 0.72
-70.43
0.72
ROC (Joel Greenblatt) (%) 64.31
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. INCY: 64.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INCY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4569.91  Med: -376.81 Max: 63.36
Current: 64.31
-4569.91
63.36
Revenue Growth (3Y)(%) 20.70
INCY's Revenue Growth (3Y)(%) is ranked higher than
73% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. INCY: 20.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INCY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.4  Med: 19.60 Max: 194.1
Current: 20.7
-61.4
194.1
EBITDA Growth (3Y)(%) 28.60
INCY's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. INCY: 28.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
INCY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.7  Med: -8.20 Max: 221.2
Current: 28.6
-31.7
221.2
» INCY's 10-Y Financials

Financials (Next Earnings Date: 2016-05-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

INCY Guru Trades in Q2 2015

Joel Greenblatt 10,363 sh (New)
Jim Simons 275,000 sh (New)
Vanguard Health Care Fund 9,411,543 sh (-7.50%)
Ken Fisher 13,695 sh (-7.90%)
» More
Q3 2015

INCY Guru Trades in Q3 2015

Paul Tudor Jones 9,555 sh (New)
John Burbank 309,627 sh (New)
Ken Fisher 14,495 sh (+5.84%)
Vanguard Health Care Fund 9,233,028 sh (-1.90%)
Joel Greenblatt 4,861 sh (-53.09%)
Jim Simons 33,200 sh (-87.93%)
» More
Q4 2015

INCY Guru Trades in Q4 2015

Frank Sands 4,420,966 sh (New)
George Soros 4,200 sh (New)
Vanguard Health Care Fund 9,615,828 sh (+4.15%)
Ken Fisher 14,818 sh (+2.23%)
Samuel Isaly 431,500 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
John Burbank Sold Out
Paul Tudor Jones 8,513 sh (-10.91%)
» More
Q1 2016

INCY Guru Trades in Q1 2016

Vanguard Health Care Fund 16,227,748 sh (+68.76%)
Ken Fisher 14,839 sh (+0.14%)
Samuel Isaly 429,400 sh (-0.49%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Incyte Corp

Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions Solid growth has attended the sector until this year
Against a backdrop of solid growth for the sector, the outperforming Vanguard Health Care Fund (Trades, Portfolio) replenished its portfolio in the first quarter with increases in 27 holdings and reductions or removal of 28 holdings. Read more...
Vanguard Boosts Stake in Incyte in 1st Quarter Guru sells holdings in CVS Health, Edwards Lifesciences, Monsanto
Vanguard Health Care Fund continued a streak of double-digit returns in 2015 with returns of 12.65%. That is below the fund’s returns levels of 2014 (28.52%) and 2013 (43.19%), but it is still in double digits, which was a considerable achievement in 2015’s challenging investing environment. Read more...
Frank Sands Acquires Stake in Netflix Guru adds to positions in Amazon and Under Armour
Much of the significant fourth-quarter investment activity from Frank Sands (Trades, Portfolio), CEO and CIO of Sands Capital Management, an investment management firm that invests in quality growth businesses across the globe, was in familiar names in North America. Read more...
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Prothena Corp. tops the list with a 148% return year-to-date
Jean M. Hynes has managed the Vanguard Health Care Fund (Trades, Portfolio) (VGHCX) since 2008, which is now composed of 82 stocks. The following are the stocks in the portfolio with the highest performance since the beginning of the year. Read more...

Ratios

vs
industry
vs
history
Forward P/E 62.89
INCY's Forward P/E is ranked lower than
87% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. INCY: 62.89 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 168.37
INCY's Price/Owner Earnings (ttm) is ranked lower than
85% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. INCY: 168.37 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
INCY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.9  Med: 184.00 Max: 773.42
Current: 168.37
9.9
773.42
P/B 74.92
INCY's P/B is ranked lower than
98% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. INCY: 74.92 )
Ranked among companies with meaningful P/B only.
INCY' s P/B Range Over the Past 10 Years
Min: 17.51  Med: 141.67 Max: 391.93
Current: 74.92
17.51
391.93
P/S 16.55
INCY's P/S is ranked lower than
60% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. INCY: 16.55 )
Ranked among companies with meaningful P/S only.
INCY' s P/S Range Over the Past 10 Years
Min: 7.13  Med: 22.78 Max: 239.71
Current: 16.55
7.13
239.71
PFCF 215.33
INCY's PFCF is ranked lower than
94% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. INCY: 215.33 )
Ranked among companies with meaningful PFCF only.
INCY' s PFCF Range Over the Past 10 Years
Min: 6.56  Med: 222.23 Max: 1176.61
Current: 215.33
6.56
1176.61
POCF 148.69
INCY's POCF is ranked lower than
94% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. INCY: 148.69 )
Ranked among companies with meaningful POCF only.
INCY' s POCF Range Over the Past 10 Years
Min: 6.52  Med: 168.02 Max: 775.18
Current: 148.69
6.52
775.18
EV-to-EBIT 240.25
INCY's EV-to-EBIT is ranked lower than
95% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. INCY: 240.25 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8436.1  Med: -8.70 Max: 1546.6
Current: 240.25
-8436.1
1546.6
EV-to-EBITDA 130.25
INCY's EV-to-EBITDA is ranked lower than
92% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. INCY: 130.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
INCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -662.5  Med: -6.95 Max: 2618.5
Current: 130.25
-662.5
2618.5
Current Ratio 5.01
INCY's Current Ratio is ranked higher than
52% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. INCY: 5.01 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 2.05  Med: 4.98 Max: 15.29
Current: 5.01
2.05
15.29
Quick Ratio 5.00
INCY's Quick Ratio is ranked higher than
54% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. INCY: 5.00 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 2.05  Med: 4.97 Max: 15.29
Current: 5
2.05
15.29
Days Inventory 24.03
INCY's Days Inventory is ranked higher than
87% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. INCY: 24.03 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 14.49  Med: 122.28 Max: 323.15
Current: 24.03
14.49
323.15
Days Sales Outstanding 55.42
INCY's Days Sales Outstanding is ranked higher than
58% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. INCY: 55.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 38.86 Max: 6447.52
Current: 55.42
12.25
6447.52
Days Payable 407.13
INCY's Days Payable is ranked higher than
93% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. INCY: 407.13 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 407.13  Med: 7019.64 Max: 32457.1
Current: 407.13
407.13
32457.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2289.67
INCY's Price/Net Current Asset Value is ranked lower than
100% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. INCY: 2289.67 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INCY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.47  Med: 12.50 Max: 3615
Current: 2289.67
1.47
3615
Price/Tangible Book 74.66
INCY's Price/Tangible Book is ranked lower than
97% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. INCY: 74.66 )
Ranked among companies with meaningful Price/Tangible Book only.
INCY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.11  Med: 6.92 Max: 118.27
Current: 74.66
1.11
118.27
Price/Median PS Value 0.73
INCY's Price/Median PS Value is ranked higher than
64% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. INCY: 0.73 )
Ranked among companies with meaningful Price/Median PS Value only.
INCY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 0.67 Max: 4.34
Current: 0.73
0.14
4.34
Earnings Yield (Greenblatt) (%) 0.44
INCY's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. INCY: 0.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INCY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 0.40 Max: 1.2
Current: 0.44
0.1
1.2

More Statistics

Revenue(Mil) $754
EPS $ -0.03
Beta0.67
Short Percentage of Float5.64%
52-Week Range $55.00 - 133.62
Shares Outstanding(Mil)187.20

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 1,009 1,325 1,526
EPS($) 0.27 1.15 2.07
EPS without NRI($) 0.27 1.15 2.07

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:ICY.Germany,
Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Frank Sands Acquires Stake in Netflix Feb 23 2016 
Top Insider Trades of the Past Week Feb 19 2016 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 

More From Other Websites
Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : April 29, 2016 Apr 29 2016
Incyte to Present at Upcoming Investor Conferences Apr 28 2016
Incyte to Present at Upcoming Investor Conferences Apr 28 2016
INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers Apr 18 2016
Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development... Apr 15 2016
Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development... Apr 15 2016
Incyte to Report First Quarter Financial Results Apr 14 2016
Incyte to Report First Quarter Financial Results Apr 14 2016
$35M deal: Incyte licenses Lilly drug for potential new use Apr 11 2016
How Has Incyte’s Jakafi Performed in the US? Apr 08 2016
What Are Incyte’s Revenue Streams? Apr 08 2016
Incyte Continues Its Growth Spree in 2015 Apr 07 2016
How Does Incyte’s Valuation Compare to Peers? Apr 07 2016
XBI Large Caps: Incyte Signs Deal with Eli Lilly Apr 07 2016
Incyte Buys Rights to Jakafi for Graft-Versus-Host Disease Apr 07 2016
INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Apr 06 2016
5 Biotechs With the Most Upside This Earnings Cycle Apr 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK